BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int 2016;36:775-82. [DOI: 10.1111/liv.13086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 Fiorino S, Bacchi-Reggiani ML, Leandri P, Loggi E, Andreone P. Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis. World J Hepatol 2017; 9(6): 333-342 [PMID: 28293383 DOI: 10.4254/wjh.v9.i6.333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang JL, Du XF, Chen SL, Yu YQ, Wang J, Hu XQ, Shao LY, Chen JZ, Weng XH, Zhang WH. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol 2015; 21(32): 9598-9606 [PMID: 26327767 DOI: 10.3748/wjg.v21.i32.9598] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Dusheiko G. Towards the elimination and eradication of hepatitis B. Journal of Virus Eradication 2015;1:4-12. [DOI: 10.1016/s2055-6640(20)31151-1] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Qian L, Fan H, Ju Y, Chen L, Li X, Ye X, Luo Y, Li C, Meng S. A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53. J Gen Virol 2019;100:1241-52. [PMID: 31204972 DOI: 10.1099/jgv.0.001289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Liu T, Sun Y, Zhou J, Yang F, Zou X, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Wang T, Ou X, Wu S, Kong Y, Wang P, Cong M, Zhang Y, You H, Jia J. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy. J Med Virol 2019;91:1499-509. [PMID: 30905065 DOI: 10.1002/jmv.25465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Song M, Sun Y, Tian J, He W, Xu G, Jing Z, Li W. Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. J Virol 2018;92:e01771-17. [PMID: 29437960 DOI: 10.1128/JVI.01771-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
9 Klumpp K, Crépin T. Capsid proteins of enveloped viruses as antiviral drug targets. Curr Opin Virol 2014;5:63-71. [PMID: 24607800 DOI: 10.1016/j.coviro.2014.02.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
10 Li XK, Zhang MX, Shao FZ, Zhou DQ, Xue JD, Liu TJ, Chi XL, Lu BJ, Wang XB, Li Q, Li J, Mao DW, Yang HS, Yang HZ, Zhao WX, Li Y, Zhang GL, Zhao YM, Zou JD, Liu MY, Zhang KK, Yang XZ, Gan DN, Li Y, Zhang P, Li ZG, Li S, Ye YA. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial. Chin J Integr Med 2020;26:330-8. [PMID: 31919749 DOI: 10.1007/s11655-020-3250-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bedre RH, Raj U, Misra SP, Varadwaj PK. Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials. Indian J Gastroenterol 2016;35:75-82. [PMID: 27083430 DOI: 10.1007/s12664-016-0632-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-476. [PMID: 30982722 DOI: 10.1016/s2468-1253(19)30042-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 14.3] [Reference Citation Analysis]
13 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
14 Peng Z, Fang G, Peng F, Pan Z, Su Z, Tian W, Li D, Hou H. Effects of Rubiadin isolated from Prismatomeris connata on anti-hepatitis B virus activity in vitro. Phytother Res 2017;31:1962-70. [PMID: 29044868 DOI: 10.1002/ptr.5945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hadziyannis SJ. Update on Hepatitis B Virus Infection: Focus on Treatment. J Clin Transl Hepatol 2014;2:285-91. [PMID: 26355326 DOI: 10.14218/JCTH.2014.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Cunha-Silva M, Marinho FRT, Oliveira PF, Lopes TM, Sevá-Pereira T, Lorena SLS, Almeida JRS. Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors. Braz J Infect Dis 2017;21:441-7. [PMID: 28554002 DOI: 10.1016/j.bjid.2017.03.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr. 2020;70:527-538. [PMID: 31977956 DOI: 10.1097/mpg.0000000000002628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
18 Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015;290:5673-5684. [PMID: 25550158 DOI: 10.1074/jbc.M114.602540] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
19 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
20 Yu H, Hou Z, Han Q, Zhang C, Zhang J. The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-α. Virol J 2013;10:270. [PMID: 23984795 DOI: 10.1186/1743-422X-10-270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Seo Y, Yano Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol 2014; 20(37): 13284-13292 [PMID: 25309065 DOI: 10.3748/wjg.v20.i37.13284] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
22 Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin XY, Ebisui E, Higuchi S, Sudoh M, Suzuki H, Takahashi N, Watashi K, Wakita T, Kakeya H, Kojima S. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One 2019;14:e0216139. [PMID: 31188831 DOI: 10.1371/journal.pone.0216139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Cao W, Li M, Zhang L, Lu Y, Wu S, Shen G, Chang M, Liu R, Gao Y, Hao H, Hu L, Yi W, Pan CQ, Xie Y. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. Biomed Res Int 2021;2021:2178143. [PMID: 33575322 DOI: 10.1155/2021/2178143] [Reference Citation Analysis]
24 Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci 2015;16:17494-513. [PMID: 26263973 DOI: 10.3390/ijms160817494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Yang Y, Zheng B, Han Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther. 2016;17:449-456. [PMID: 26934469 DOI: 10.1080/15384047.2016.1156257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
26 Chu X, Wu B, Fan H, Hou J, Hao J, Hu J, Wang B, Liu G, Li C, Meng S. PTD-fused p53 as a potential antiviral agent directly suppresses HBV transcription and expression. Antiviral Res 2016;127:41-9. [PMID: 26784393 DOI: 10.1016/j.antiviral.2016.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]